RevolKa, a Tokyo, Japan-based biotech company advancing an AI-driven protein engineering technology platform, raised US$0.7M and completed a US$1.7M in Series A funding.
D3 co-led the Series A extension round along with DEEPCORE.
The company intends to use the funds to expand its drug discovery and development activities.
Founded in April 2021, RevolKa is a biotechnology company which aims to create novel proteins useful for therapeutics and industries by using proprietary technology, aiProtein®.
The company also announced the launch of a drug discovery program for rare diseases on July 30th, 2024. Some of its drug candidates in this program have achieved positive in vitro proof-of-concept.
RevolKa also has laboratories located in Sendai.
FinSMEs
30/08/2024